Delays in protease inhibitor use in clinical practice

Area of Science:

• Infectious Diseases
• Clinical Medicine
• Pharmacology

Background:

• Protease inhibitors are critical for managing HIV infection.
• Timely initiation of antiretroviral therapy, including protease inhibitors, is essential for optimal patient outcomes.
• Understanding factors influencing treatment delays is crucial for improving HIV care.

Purpose of the Study:

• To identify clinical factors associated with delayed initiation of protease inhibitor therapy in patients with HIV.
• To analyze the impact of patient characteristics on the timing of protease inhibitor prescription.

Main Methods:

• Retrospective chart review and telephone survey of 190 patients with HIV and viral load >10,000 copies/ml.
• Cox proportional hazards modeling was used to assess factors associated with delayed protease inhibitor initiation.

Main Results:

• Higher CD4 cell counts, history of depression, and history of injection drug use were significantly associated with delayed protease inhibitor initiation.
• Higher viral load and a history of pneumocystis pneumonia were associated with delayed initiation in univariate analysis but not consistently in multivariate models.
• Factors such as AIDS and history of pneumocystis pneumonia were associated with earlier initiation in univariate analysis.

Conclusions:

• Clinical factors including higher CD4 cell counts, depression, and injection drug use are linked to significant delays in protease inhibitor therapy for HIV.
• While some delays may be clinically justified, enhanced provider and patient education could improve adherence and timely treatment.
• Further research is needed to explore the reasons for these delays and assess their clinical appropriateness.